RxDoctor Payments DataLook up a doctor →

Sheldon Freedman, MD

Urology · Las Vegas, NVNPI 1659483444

Payments from drug & device makers

$592,292in general payments, 2019–2025

Across 369 payments — averaging $1605.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Laborie Medical Technologies Corp.$359K
  • AbbVie$193K
  • Urovant Sciences Inc$24K
  • Sumitomo Pharma America, Inc.$3K
  • Teleflex LLC$3K
  • Coloplast$2K
  • plus $8K from 33 others
$1,393in research payments, 2019–2025

Across 1 payment — averaging $1393.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neotract Inc.$1K

What the payments were for

  • Travel & lodging$8568%
  • Food & beverage$8,00378%
  • Education$1,43314%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$592,292 in reported general payments places this provider in the 95th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$489,789
Medicare patients
789
Services billed
7,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron88$85,469
GemtesaVibegron40$43,052
IntrarosaPrasterone (Dhea)11$9,005
Potassium Citrate ErPotassium Citrate67$7,243
Tamsulosin Hcl333$5,557
Finasteride283$4,267
Alfuzosin Hcl ErAlfuzosin Hcl89$1,903
Silodosin20$1,596
ValacyclovirValacyclovir Hcl25$1,472
Oxybutynin Chloride ErOxybutynin Chloride34$1,452
Bicalutamide29$1,174
Solifenacin Succinate21$1,046
CefuroximeCefuroxime Axetil78$862
Dutasteride17$433
Metronidazole69$369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,521$85,46988 claims
Sumitomo Pharma America, Inc.Gemtesa$3,076$43,05240 claims
AMAG Pharmaceuticals, Inc.Intrarosa$121$9,00511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 63 urology providers in Nevada.

Other urology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →